Suppr超能文献

免疫重建在同种异体移植后 100 天是否具有临床意义?

Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?

机构信息

Division of Hemato-oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

Division of Hemato-oncology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.

出版信息

Korean J Intern Med. 2020 Jul;35(4):957-969. doi: 10.3904/kjim.2018.414. Epub 2020 Apr 21.

Abstract

BACKGROUND/AIMS: Immune reconstitution following allogeneic hematopoietic stem cell transplantation (HSCT) is affected by multiple variables during the transplantation.

METHODS

We assessed the clinical factors contributing to immune function reconstitution at 100 days post-allogeneic HSCT in 114 patients receiving fludarabine-based conditioning. Immunophenotypic analysis using flow cytometry was performed to evaluate the percentage and the absolute numbers of T-cell subsets, natural killer cells, and B-cells as clinical outcomes.

RESULTS

Tacrolimus-based graft-versus-host disease (GVHD) prophylaxis, T-cell depletion, and acute GVHD were significantly associated with delayed immune reconstitution of T-cell subsets. The incidence of chronic GVHD was significantly increased in the normal recovery group compared to the abnormal group (p = 0.01). Epstein-Barr virus reactivation was more frequently observed in the abnormal group of T-cell subsets (p = 0.045). All viral reactivation events including cytomegalovirus reactivation appeared to be more frequent in the abnormal group of T-cell subsets.

CONCLUSION

The immune recovery status post-allogeneic HSCT was affected by GVHD prophylactic regimens, especially in cases receiving tacrolimus-based GVHD prophylaxis, T-cell depletion, and possibly those manifesting acute GVHD. Delayed immune reconstitution might increase the morbidity due to viral reactivation. Treatment strategies are needed to prevent infectious complications and enhance immune reconstitution based on the immune recovery status following allogeneic HSCT with fludarabine-based conditioning.

摘要

背景/目的:异基因造血干细胞移植(HSCT)后的免疫重建受移植过程中多个变量的影响。

方法

我们评估了 114 例接受氟达拉滨为基础的预处理的患者在异基因 HSCT 后 100 天免疫功能重建的临床因素。使用流式细胞术进行免疫表型分析,以评估 T 细胞亚群、自然杀伤细胞和 B 细胞的百分比和绝对数量作为临床结果。

结果

他克莫司为基础的移植物抗宿主病(GVHD)预防、T 细胞耗竭和急性 GVHD 与 T 细胞亚群的延迟免疫重建显著相关。与异常组相比,慢性 GVHD 在正常恢复组的发生率显著增加(p = 0.01)。异常 T 细胞亚群组中更频繁地观察到 EBV 再激活(p = 0.045)。所有病毒再激活事件,包括巨细胞病毒再激活,在异常 T 细胞亚群组中似乎更为频繁。

结论

异基因 HSCT 后的免疫恢复状态受 GVHD 预防方案的影响,特别是在接受他克莫司为基础的 GVHD 预防、T 细胞耗竭和可能表现为急性 GVHD 的患者中。延迟的免疫重建可能会因病毒再激活而增加发病率。需要根据氟达拉滨为基础的预处理的异基因 HSCT 后的免疫恢复情况,制定预防感染并发症和增强免疫重建的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b539/7373953/92a403a5f6e5/kjim-2018-414f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验